Blue Earth Therapeutics Expands Partnership With Seibersdorf Labor to Manufacture 225Ac-rhPSMA-10.1

Blue Earth Therapeutics Ltd, a subsidiary of Bracco and a pioneer in next-generation therapeutic radiopharmaceuticals, has broadened its manufacturing agreements with Seibersdorf Labor GmbH to include the production of its investigational 225Ac-based radioligand therapy. This expansion ensures future supply to clinical trial sites in the UK, EU, and US. The therapy, 225Ac rhPSMA-10.1, is an investigational radiohybrid Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical and represents the second candidate in Blue Earth Therapeutics' oncology development program.

David E. Gauden, CEO of Blue Earth Therapeutics Ltd, expressed satisfaction with the expanded partnership. He emphasized that the new 225Ac-based investigational product has the potential for high purity and stability. This collaboration will support clinical trial sites in London and potentially other regions. Gauden praised Seibersdorf as an excellent and collaborative partner and looked forward to future projects together.

Dr. Markus Neumann, Managing Director of Seibersdorf Labor GmbH, highlighted that this is their first project involving the 225Ac radioisotope. To support it, they have implemented dedicated infrastructure and services. Neumann expressed excitement about developing in-house expertise for 225Ac and expanding projects with Blue Earth Therapeutics to include this new agent. He looked forward to delivering doses to treat patients in clinical trials and acknowledged Blue Earth Therapeutics as a supportive partner in expanding capabilities.

Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) compounds consist of a radiohybrid Prostate-Specific Membrane Antigen-targeted receptor ligand. This ligand attaches to and is internalized by prostate cancer cells. These compounds can be radiolabeled with imaging isotopes for PET imaging or therapeutic isotopes such as 177Lu or 225Ac for therapeutic use. They hold significant potential for precision medicine in treating prostate cancer. This technology originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018 and therapeutic rights in 2020. The therapeutic application has been sublicensed to Blue Earth Therapeutics. Currently, rhPSMA compounds from Blue Earth Therapeutics have not received regulatory approval.

Blue Earth Therapeutics, part of the Bracco family, is a clinical-stage company committed to advancing next-generation targeted radiotherapeutics to treat cancer patients. The company boasts extensive management expertise in radiopharmaceutical and oncology drug development, as well as biotechnology startup experience. Blue Earth Therapeutics aims to innovate and improve current technologies, rapidly advancing new targeted therapies for serious diseases. The company has an emerging pipeline focused initially on prostate cancer. It is an indirect subsidiary of Bracco Imaging S.p.A. and is based in Oxford, UK.

Bracco Imaging S.p.A., a segment of the Bracco Group, is a global leader in diagnostic imaging. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions. Its comprehensive portfolio covers key diagnostic imaging modalities, including X-ray imaging, MRI, Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and PET imaging agents. These solutions support clinical management and care for cancer patients in areas of unmet medical need. In addition to imaging agents, Bracco Imaging's evolving portfolio includes medical devices, advanced administration systems, and dose-management software. In 2019, Bracco Imaging expanded its product portfolio to include oncology nuclear imaging solutions in the urology segment and other specialties through the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics to develop radiopharmaceutical therapies.

Seibersdorf Labor GmbH specializes in high-quality laboratory and analytical work, application-oriented research and development, and consulting and training. The company offers services and expertise in systems development, production and quality control of radiopharmaceuticals, anti-doping and forensic analyses, radiation protection, ionizing and non-ionizing radiation, radio frequency engineering, and electromagnetic compatibility. Seibersdorf Laboratories' experts represent Austria on various international committees.